comparemela.com

Latest Breaking News On - Mark bodenrader - Page 1 : comparemela.com

Cerevel Therapeutics (NASDAQ:CERE) Sees Strong Trading Volume

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) shares saw an uptick in trading volume on Tuesday . 1,343,879 shares were traded during trading, a decline of 20% from the previous session’s volume of 1,682,243 shares.The stock last traded at $41.20 and had previously closed at $42.57. Analyst Upgrades and Downgrades A number of […]

United-states
Mark-bodenrader
Piper-sandler
Scott-akamine
Jefferies-financial-group
Avoro-capital-advisors
Jpmorgan-chase-co
Morgan-stanley
Cerevel-therapeutics-company-profile
Vanguard-group-inc
Cerevel-therapeutics-holdings-inc
Perceptive-advisors

Form PRER14A Cerevel Therapeutics

Form PRER14A Cerevel Therapeutics
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Massachusetts
United-states
Japan
Delaware
North-chicago
Illinois
Russia
Boston
Ukraine
State-of-delaware
Iran
Crimea

Insider Selling: Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Insider Sells $326,762.38 in Stock

Insider Selling: Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Insider Sells $326,762.38 in Stock
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

United-states
Mark-bodenrader
Charles-schwab-investment-management-inc
Jefferies-financial-group
Cerevel-therapeutics-holdings-inc
Cantor-fitzgerald
Mirae-asset-global-investments-co
Jpmorgan-chase-co
Cerevel-therapeutics-company-profile
Affinity-asset-advisors
Morgan-stanley
Nasdaq

Insider Selling: Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) Insider Sells 7,889 Shares of Stock

Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE – Get Free Report) insider Mark Bodenrader sold 7,889 shares of the business’s stock in a transaction on Wednesday, December 20th. The stock was sold at an average price of $41.42, for a total value of $326,762.38. Following the completion of the transaction, the insider now directly owns 17,724 shares […]

United-states
Mark-bodenrader
Piper-sandler
Cerevel-therapeutics-company-profile
Prudential-financial-inc
Morgan-stanley
Cantor-fitzgerald
Cerevel-therapeutics-holdings-inc
Nasdaq
Metlife-investment-management
Securities-exchange-commission
Cerevel-therapeutics-holdings

Mizuho Trims Cerevel Therapeutics (NASDAQ:CERE) Target Price to $25.00

Cerevel Therapeutics (NASDAQ:CERE – Free Report) had its price target decreased by Mizuho from $29.00 to $25.00 in a research report released on Monday, MarketBeat reports. Mizuho currently has a neutral rating on the biotechnology company’s stock. A number of other research analysts have also weighed in on the stock. Bank of America lowered shares […]

United-states
America
Mark-bodenrader
Cerevel-therapeutics-company-profile
Wells-fargo-company
Morgan-stanley
Barclays-plc
Boone-capital-management
Vanguard-group-inc
Cerevel-therapeutics-holdings-inc
Cerevel-therapeutics
Free-report

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.